Acumen Pharmaceuticals to Report Third Quarter Financial Results on November 13, 2023
07 November 2023 - 8:01AM
Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the
“Company”), a clinical-stage biopharmaceutical company developing a
novel therapeutic that targets toxic soluble amyloid beta oligomers
for the treatment of Alzheimer’s disease, today announced that the
Company will report third quarter financial results on Monday, Nov.
13, 2023. The Company will host a conference call and live audio
webcast at 8:00 a.m. ET to provide a business and financial update.
To participate in the live conference call, please
register using this link. After registration, you will be informed
of the dial-in numbers including PIN. Please register at least one
day in advance.
The webcast audio will be available via this link.
An archived version of the webcast will be available for at
least 30 days in the Investors section of the Company's website at
www.acumenpharm.com.
About Acumen Pharmaceuticals, Inc.
Acumen, headquartered in Charlottesville, VA, with additional
offices in Indianapolis, IN and Newton, MA, is a clinical-stage
biopharmaceutical company developing a novel therapeutic that
targets toxic soluble amyloid beta oligomers (AβOs) for the
treatment of Alzheimer’s disease (AD). Acumen’s scientific founders
pioneered research on AβOs, which a growing body of evidence
indicates are early and persistent triggers of Alzheimer’s disease
pathology. Acumen is currently focused on advancing its
investigational product candidate, ACU193, a humanized monoclonal
antibody that selectively targets toxic soluble AβOs, following
positive topline results in INTERCEPT-AD, a Phase 1 clinical trial
involving early Alzheimer’s disease patients. For more information,
visit www.acumenpharm.com.
Investors:
Alex Braunabraun@acumenpharm.com
Media: AcumenPR@westwicke.com
Acumen Pharmaceuticals (NASDAQ:ABOS)
Historical Stock Chart
From Apr 2024 to May 2024
Acumen Pharmaceuticals (NASDAQ:ABOS)
Historical Stock Chart
From May 2023 to May 2024